Increased iron levels can also generate peroxyl/ alkoxyl radicals due to Fe 2+ -dependent lipid peroxidation [11] . These reactive oxygen species (ROS) can damage cellular macromolecules, including proteins, lipids and DNA. Under normal conditions, several detoxification systems and antioxidant defense mechanisms exist to prevent this damage; for example, catalase and glutathione peroxidase quickly convert H 2 O 2 to water, helping to ensure that ROS-induced damage is minimal in the brain [12] . However, when the formation of ROS exceeds cells' detoxification/ antioxidant systems, cells can experience oxidative stress. Iron-induced oxidative stress is particularly dangerous because it can cause further iron release from iron-containing proteins, such as ferritin (Ft), heme proteins and iron-sulfur (Fe-S) clusters, forming a destructive intracellular positive-feedback loop that exacerbates the toxic effects of brain iron overload [13] .
Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders
Trace metals, such as iron, copper, zinc, manganese and cobalt, are essential cofactors for many cellular enzymes. Extensive research on iron, the most abundant transition metal in biology, has contributed to an increased understanding of the molecular machinery involved in maintaining its homeostasis in mammalian peripheral tissues. However, the cellular and intercellular iron-transport mechanisms in the CNS are still poorly understood. Accumulating evidence suggests that impaired iron metabolism is an initial cause of neurodegeneration and several common genetic and sporadic neurodegenerative disorders have been proposed as being associated with dysregulated CNS iron homeostasis. This review aims to provide a summary of the molecular mechanisms of brain iron transport. Our discussion is focused on iron transport across endothelial cells of the blood-brain barrier and within the neuro-and glial-vascular units of the brain, with the aim of revealing novel therapeutic targets for neurodegenerative and CNS disorders. ) occurs via receptor-mediated endocytosis of Tf (vesicular import pathway IN2). Fe 3+ ions form complexes with the high affinity iron binding protein, Tf, which then binds to specific membrane-bound TfR. After endocytosis, the acidic environment of the early endosomes (compartment specificity defined by a small GTPase Rab5) triggers the release of Fe 3+ from the Tf-TfR complex, which is recycled to the plasma membrane via Rab11-positive recycling endosomes (vesicular export pathway EX2). Members of the Steap family of ferric reductases localize to the endosome and reduce Fe 3+ (ferric) to its Fe 2+ (ferrous) form before Fe 2+ is released into the cytosol by the DMT1 in an H + -dependent manner. Fe 3+ may also be sorted into Rab7-positive LE and LY, where it is reduced into Fe 2+ by Steap proteins in LE or LY. In LE and LY, Fe 2+ can also be released by other endolysosomal iron-release channels/transporters such as TRPML1, Nramp1 (in macrophages), or Zip8. Other sources of lysosomal Fe 3+ include Fe 3+ -laden Ft complexes and autophagic ingestion of damaged organelles such as mitochondria. Other mechanisms for receptor-mediated iron uptake exist in oligodendrocytes and other cells, where Fe 3+ ions bind the Ft receptors (Scara5 or Tim-2) and undergo receptor-mediated endocytosis (vesicular iron import pathway IN1). This pathway depends on lysosomal degradation of Ft-Fe complexes before iron is released into the cytosol. Lysosomal Fe 3+ or Ft-Fe complexes may also be exported out of the cells via lysosomal exocytosis (vesicular export pathway EX1). In some cell types, uptake of non-Tf bound iron (NTBI) A cardinal pathology associated with several common neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease, is iron accumulation in the brain, coincident with sites of extensive neuronal cell death [5, 7, 8, [14] [15] [16] [17] . Normally, iron-rich regions in the brain, such as the globus pallidus, red nucleus, substantia nigra (SN), putamen and caudate nucleus, seem to be most susceptible to neurodegenerative processes [14] . During the typical aging process, iron accumulation also occurs in multiple regions of the brain known to be more vulnerable to age-dependent neurodegeneration [8, 9] . For example, iron invasion with age predominates in motor areas of the brain, such as the basal ganglia, which may explain the motor deterioration commonly exhibited in many neurodegenerative diseases.
The question remains whether iron invasion and subsequent radical formation is a primary or secondary event in neurodegenerative diseases.
Recent evidence suggests that iron invasion is an initial cause of neuronal cell death and axonal degeneration [5, 8, 18] . Several inherited disorders of iron metabolism in humans are known to display neurodegeneration with brain-iron accumulation (NBIA) [14] . This group of genetically hetero geneous progressive disorders includes NBIA type I (formerly Hallervorden-Spatz syndrome), neuroferritinopathy, infantile neuroaxonal dystrophy-1 (INAD1), and aceruloplasminemia (taBle 1) . Detailed studies of these disorders suggest that an iron gradient formed in brain tissues is causal for triggering neuronal toxicity [19] [20] [21] [22] . Other CNS disorders that have been proposed to have an iron-dependent component include Friederich's ataxia [17] , restless leg syndrome [23] , ischemic/hemorrhagic stroke [24] and multiple sclerosis [16] . Dong et al. recently demonstrated that transient receptor potential mucolipin 1 (TRPML1), the gene MCOLN1 that is mutated in mucolipidosis type IV (ML4) [26] . Furthermore, several studies of iron regulatory proteins using transgenic rodents suggest that iron may be a pathogenic factor for neurodegeneration [27, 28] . Finally, iron chelators [8, 29, 30] and genetic manipulation resulting in low iron levels [29, 31, 32] are found to be neuroprotective.
Although we focus on iron toxicity in this review, it is worth mentioning that other transition metals have also been implicated in neurodegenerative disorders [33] . For example, copper accumulation has also been implicated in AD [33, 34] . As Cu + is also able to catalyze the Fenton reaction, copper accumulation may also facilitate radical formation during oxidative stress [33] . Under different pathological conditions, iron and other transition metals accumulate in different brain regions at different levels [33, 34] . Therefore, it is difficult to isolate iron-specific toxicity. Furthermore, there is crosstalk between iron and copper toxicity, as ceruloplasmin (Cp), the major ferroxidase, functions in a Cu-dependent manner [35] . Nevertheless, the abundance of iron suggests a major role of iron toxicity in neurodegeneration.
Cellular iron transport in the peripheral tissues
In normal human plasma, serum iron (~20 µM) exists primarily in the Fe 3+ form and is complexed with the high-affinity iron-binding protein transferrin (Tf; ~40 µM) in a 2:1 ratio (TfFe 2 ; FiguRe 1) . Hence, Tf is only partially (~25%) saturated. Under iron overload conditions, however, Tf is saturated and non transferrin-bound iron (NTBI) can reach 1-20 µM [36] . In the cerebrospinal fluid (CSF), in which the Tf concentration is low (< 0.5 µM), NTBI can reach a sub-micromolar concentration (< 1 µM) [37, 38] . Depending on the microenvironment and availability of ferric reductases, NTBI can exist in both Fe 3+ and Fe 2+ forms. Inside the cell, free iron in its reduced form (Fe 2+ ) constitutes the 'labile iron' pool (~2-3 µM) [39] FiguRe 1 ). Fe 2+ may also efflux from the cell via transmembrane channels or transporters (non vesicular iron export pathway EX3; FiguRe 1 ). Most mammalian cells transport iron using a combination of these iron import and export pathways.
Iron transport in enterocytes
Systemic iron levels are principally regulated at the level of absorption by the small intestine [40, 41] . Intestinal iron absorption involves trans cellular transport mediated by enterocytes (polarized epithelial cells that line the lumen of the intestines). Iron crosses the apical brush border membrane, traverses the cell, and then exits across the basolateral membrane to enter the blood plasma [4, 42, 43] . Dietary iron, existing primarily in the insoluble Fe 3+ form, is first reduced to Fe 2+ by duodenal cytochrome B (DcytB, also called CYBRD1), a ferrireductase present on the apical membranes of entero cytes [44] . Fe 2+ then enters the enterocytes by divalent metal transporter-1 (DMT1, Slc11a2), an H + -dependent Fe 2+ transporter (nonvesicular iron import pathway IN3; FiguRe 1 ) expressed on the apical membrane [45] . Once inside, Fe 2+ can leave the enterocyte through ferroportin (Fpn), an Fe 2+ channel/ transporter (nonvesicular iron export pathway EX3; FiguRe 1 ) expressed on the basolateral membrane [46] . Released Fe 2+ is quickly oxidized into the bio-unavailable Fe 3+ form via a membrane bound or cytosolic ferroxidase, such as hephaestin (Hp) [47] , or Cp [21] . In order to be available for use, Fe 3+ enters the plasma by forming complexes with high-affinity ironbinding proteins, such as Tf, or with low-affinity iron-binding molecules, such as citrate, ascorbate or ATP (FiguRe 1). The inability to maintain sufficient iron levels in the plasma is defined as iron deficiency, often associated with anemia, while excessive iron absorption is termed iron overload. [40, 41] . The acidic environment of Rab5-positive early endosomes triggers the release of Fe 3+ from the Tf-TfR complex, which is sorted into Rab11-positive RE before trafficking to the cell membrane and subsequent exocytosis. In erythroid precursor cells, specifically, the endosomal ferric reductase six-transmembrane epithelial antigen of the prostate 3 (Steap3) reduces Fe 3+ to Fe
which is then released into the cytosol by DMT1 in a H + -dependent manner [45] . Ferrous iron in the cytosol comprises the 'labile iron' pool and represents iron that is directly available for cellular utilization. The majority of cytosolic Fe 2+ however, is transported into mitochondria by the iron importer Mfrn for the synthesis of iron-sulfur (Fe-S) clusters and biogenesis of heme [49] .
If not used immediately, cytosolic Fe 2+ can also be stored in ferritin-Fe 3+ complexes, cytoplasmic iron storage proteins [13] . These complexes are eventually degraded in the lysosome, releasing reactive Fe 2+ [50] via DMT1. In addition to utilization and storage, iron can also be released from the cell by the iron exporter Fpn (nonvesicular iron export pathway EX3; FiguRe 1) [46] .
Iron transport in most mammalian cells
Most other mammalian cell types recruit the cellular iron-transport machinery that is used by enterocytes and erythroid precursor cells. This includes using the Tf-TfR system for iron import and Fpn for iron export. Intracellular iron-transport machinery, however, may differ significantly. As DMT1 is specifically expressed on the endosomes of erythroid precursor cells, but not all cells [45] , genetic evidence suggests that a DMT1-independent iron release mechanism must exist in the endolysosomes of most cells [51] . Dong et al. recently characterized a Iron is sequestered in a nonreactive state in the blood plasma by Tf (~40 µM). Material transport from the blood plasma into the brain is limited by the BBB, which is formed by tight junctions between the BVECs. TfRs line the lumen of the brain microvasculature and bind circulating Tf-Fe 2 (~10 µM) and facilitate iron uptake into BVECs via receptormediated endocytosis. Two models for BVEC iron export are shown. The DMT1/ Fpn-independent pathway releases Fe 3+ or Tf-Fe 2 through the exocytosis of recycling endosomes (vesicular export pathway). Tf (mainly secreted from oligodendrocytes) concentration (<0.5 µM) is low in the cerebrospinal fluid. Thus, the majority of Fe 3+ forms complexes with ascorbate, citrate, and ATP as NTBI (~1 µM). Citrate and ATP are released from astrocytes. DMT1/Fpn-dependent (nonvesicular export) pathway releases Fe 2+ , which is rapidly converted into Fe 3+ via Cp in the abluminal membranes. Alternatively, astrocytic foot processes form close associations with BVECs, and polarized DMT1 expression in these astrocytic end-feet may facilitate rapid Fe 2+ uptake after release (from BVECs) into the perivascular space of the brain. Neither astrocytes nor oligodendrocytes express detectable levels of TfR. Oligodendrocytes can take up iron via the Ft receptor Tim-2. In addition, oligodendrocytes may also uptake NTBI via DMT1 or other nonvesicular iron import mechanisms. The axons of neurons are wrapped with the myelin sheath, which is made in oligodendrocytes in an iron-dependent manner. BBB: Blood-brain barrier; BVEC: Brain vascular endothelial cell; Cp: Ceruloplasmin; Fpn: Ferroportin; Ft: Ferritin; MS: Myelin sheath; N: Nucleus; Tf: Transferrin; TfR: Transferrin receptor.
future science group novel pathway for iron release from the LEL, mediated by TRPML1 [26] . Mutations in TRPML1 cause the neurodegenerative disease ML4, which in some cases presents as irondeficiency anemia (taBle 1) . TRPML1 is ubiquitously expressed and functions as a conduit for endolysosomal iron release [26] . The electrophysiological properties of TRPML1 are somewhat similar to those of DMT1. Both iron-carrying currents are inwardly rectifying (cations flowing out of the endolysosome), which is consistent with a role in iron release from the vesicular lumen. Like DMT1, TRPML1 conducts Fe 2+ but not Fe 3+ . Hence, a putative ferric reductase, presumably one of the Steap proteins [48, 52] , is required for TRPML1-mediated Fe 2+ release from LEL. Like DMT1, low pH (the environment of endolysosomes) potentiates Fe 2+ permeation of TRPML1. Although the function of TRPML1 is similar to DMT1, its localization in specific endocytic compartments is distinct from that of DMT1. While DMT1 can be detected in lysosomes, the quasi-steady-state location for DMT1 is early or late endosomes [4, 53] . On the other hand, TRPML1 is primarily localized in LELs. Therefore, TRPML1 is localized in overlapping but later endocytic compartments compared with DMT1. Consistent with a role for TRPML1 in endolysosomal iron release, TRPML1-deficient fibroblast cells exhibit lysosomal iron overload, as well as cytosolic iron deficiency [26] , suggesting defective iron transport across LEL membranes (FiguRe 1). However, as TRPML1 is also permeable to Ca 2+ , it is unlikely that TRPML1 is fully dedicated to intra cellular iron metabolism. Other cell-typespecific endolysosomal iron-release proteins may exist. For example, Nramp1 (Scl11a1), a DMT1-related proton-dependent iron transporter, is expressed in the lysosomes of macrophages [54] . Similarly, TRPML2, a homologue of TRPML1 and also a potential iron-release channel in LEL [26] , is expressed in macrophages and B cells [55] . Additionally, ZIP8 (Slc39a8), previously known as a zinc transporter, has also recently been implicated in endolysosomal iron release [56] .
The biologic reason for the existence of multiple iron release mechanisms remains unclear. For simplicity, we refer to DMT1 as an endosomal (early, recycling and late) Fe 2+ release pathway, and TRPML1/2 and Nramp1 as LEL ironrelease pathways [54] . Importantly, the source of iron may determine the primary release mechanism. For example, iron acquired through the Tf-TfR cycle is likely to be released via DMT1, which is localized in the early endocytic compartments. Thus, endosomal iron release is mainly due to DMT1. Consistent with this notion, DMT1 is crucial for iron uptake by erythroid precursor cells [51] , in which the dominant uptake pathway is Tf-dependent. On the other hand, TRPML1/2 and Nramp1 pathways may be used for iron release following lysosomal degradation of Ft-Fe complexes and autophagic/ phagosomal ingestion of iron-containing macromolecules [4] . In a scenario where macrophages recycle senescent red blood cells, Nramp1 may serve as the main release channel/transporter in the lysosome [4, 54] . Following lysosomal degradation of Ft-Fe complexes and iron-containing macromolecules, TRPML1/2 may be the primary release channel in LEL. Additionally, both DMT1-and TRPML1-dependent mechanisms may co-exist in some cell types, such as neurons [26, 45] . As endosomes undergo rapid Rabdependent sorting, a certain amount of iron from the Tf cycle may not be released into the cytosol before being sorted into LELs. Thus, DMT1 and TRPML1 may mediate iron release in a sequential manner. In cells with dual expression of DMT1 and TRPML1, impairment in DMT1-mediated endosomal iron release may be tolerated because iron entering the late endocytic pathways can still be released via TRPML1.
The regulation of iron release pathways is poorly understood. Regulators of intracellular traffic may play a role in iron metabolism by affecting both vesicular and nonvesicular iron transport pathways. For example, it was demonstrated that Mon1a, a protein involved in multiple steps of intracellular trafficking, affects cellular iron metabolism in an Fpn-dependent manner [57] . Rab proteins are a family of small GTPases that are known to control organelle identity and the specificity of intracellular membrane traffic [58] . For example, Rab5, Rab11 and Rab7 are primarily localized in the early endosome, RE and LEL, respectively (FiguRe 1) . Impaired Rab5 function in zebrafish reportedly causes iron-deficiency anemia [59, 60] . Future research may reveal the role of vesicular trafficking in regulation of cellular iron transport.
Brain iron uptake across the BBB The brain, unlike most other organs in the body, rests behind a vascular barrier. Unlike peripheral endothelia, endothelial cells within the brain vasculature are bound together by tight junctions, resulting in a physical barrier to future science group material exchange between the tissues and fluids of blood and brain. Therefore, the brain cannot take up iron directly from the circulatory system. The choroid plexus epithelium, comprised of ependymal cells, separates the blood from the ventricular CSF. Although ependymal cells can mediate iron absorption into the brain from the blood, their contribution is thought to be rather small [61] . The major uptake pathway is mediated by the BBB, which is formed by cerebrovascular endothelial cells (or brain vascular endothelial cells [BVECs] ) (FiguRe 2) . Unlike small gas molecules, such as O 2 and CO 2 , which can diffuse freely across lipid membranes into the brain, iron crosses BVECs in a multistep transcellular process similar to that of enterocytes in the duodenum.
Transferrin-dependent and -independent iron import into BVECs
The initial observation that TfR is expressed on the luminal side of brain capillaries suggested a mechanism for iron transport across the BBB through TfR-mediated endocytosis into BVECs [62] . Now, accumulated evidence from functional and genetic studies reveals that, indeed, Tf-Tf R does play a primary role in iron uptake across the BBB [5, 7, 37, 63, 64] (FiguRe 2) . The Tf-TfR-dependent iron uptake system in BVECs is similar to that used in most cell types (FiguRe 1) .
Transferrin-independent mechanisms may also contribute to iron transport across the BBB [1-3,61,64-66]. As hypotransferrinemic mice (<1% of normal circulating Tf ) have reportedly normal amounts of iron in the brain, significant contributions from Tf-independent mechanism(s) of brain iron uptake must exist [67] . While iron may also be taken up to BVECs by Tf homologues, such as lactoferrin or melanotransferrin [1] , the extent of this activity is still unclear [2] .
Non transferrin-bound iron can enter BVECs through both vesicular and nonvesicular import mechanisms (FiguRe 1) . Fe 3+ may form complexes with non-Tf iron-binding proteins, such as secreted Ft in the serum [68] . Scara5 [69] and Tim-2 [70] , have both been recently demonstrated to function as Ft receptors (FiguRe 1) . Because a molecule of Ft can bind as many as 4500 iron atoms, these newly identified receptors may play an important role in providing iron for highly iron-dependent processes, such as organogenesis [69] and myelination [6] , during development. The existence and relative contribution of Ft receptor-dependent iron uptake in BVECs is still unclear. Nonvesicular import pathways may provide a direct mechanism to cross the BBB. Since the brains of DMT1-compromised rats containing the Belgrade hypomorphic mutation (G185R) show decreased iron levels in the brain, it was thought to play a direct role in brain iron uptake [61] . However, it is not clear whether DMT1 is actually expressed in BVECs [61, 71] . Thus, it is necessary to investigate whether other nonvesicular iron importers (IN4, IN5 and IN6; FiguRe 1 ) are expressed on the luminal membranes of BVECs. Although DMT1 transports iron at the acidic pH of the endosome, it may also be able to function as an Fe 2+ importer at the neutral pH of the lumen [72] .
Intracellular iron transport in BVECs
While it is well established that iron enters brain endothelial cells through Tf-dependent receptormediated endocytosis, there is little agreement on the mechanisms of intracellular transport that ensure iron eventually traverses the abluminal membrane and enters the brain. The controversy of DMT1 expression in BVECs [61, 71] may determine how iron is transported intracellularly. Given its ubiquitous expression pattern, TRPML1 is likely to play an important role in endolysosomal iron release in BVECs [26] . Whether other iron release proteins, such as ZIP8 and TRPML2, are expressed in BVEC cells is not yet known. Additionally, it is not known which ferric reductase(s) are expressed in the endosomes and lysosomes of BVECs, though they likely express one or more of the Steap proteins [48, 52] .
Iron export across the abluminal membrane Ferroportin is currently the only known iron exporter [46] , making it a natural candidate to export iron across abluminal membranes. However, it is unclear whether it is expressed [61, 73, 74] in BVECs. It is also possible that the expression level of Fpn is low in these cells. Since knock-out of Fpn globally in mice results in embryonic lethality [75] , an endothelium-or BVEC-specific inactivation of Fpn in mice may be necessary to provide a definite answer on whether Fpn plays a role in iron transport across the BBB. DMT1/Fpn-independent export mechanisms may also account for iron transport across the abluminal membranes of BVECs [74] . Moos et al. propose that exocytosis of the RE containing Compared with plasma, CSF/ISF solutions contain much lower concentrations of Tf (<0.5 µM), but several-fold higher concentrations of citrate and ascorbate [37] . Thus, citrate and ascorbate in the ISF may serve as possible coordination partners for released Fe 3+ (FiguRe 1) . Additionally, astrocytes form close associations with the microvasculature of the brain and are known to release ATP and other nucleotides that may play a role in this exocytosis-dependent abluminal membrane iron transport [76] . Indeed, significant sources of NTBI exist in the brain bound to citrate, ascorbate and ATP [5] . Nevertheless, this model is lacking explanation of how abluminally exposed apo-Tf laden TfRs are recycled or degraded, since very little serum Tf crosses into the BBB. Another potential iron export mechanism in BVECs is lysosomal exocytosis (vesicular iron export pathway EX1; FiguRe 1) . Lysosomal exocytosis has recently been demonstrated to occur in all mammalian cell types studied thus far [77] . As Ft-receptor-(Scara5 or Tim-2) mediated endocytic iron uptake and reutilization of Ft-bound storage iron require lysosomes [50] , this pathway may not only export iron but also provide secreted Ft or its degraded product hemosiderin to the CSF/ISF. Direct evidence for this lysosome-mediated iron export is currently still lacking. Nevertheless, if both exocytotic types of iron-export mechanisms coexist in BVECs, manipulations of compartment-specific Rab proteins may help determine the extent to which iron absorption by BVECs relies on the Rab7-dependent lysosomal pathway versus the Rab11-dependent endosomal pathway.
Iron transport in neurons & glia
Iron transport in astrocytes Astrocytic perivascular foot processes surround the vascular barrier formed by BVECs just outside the basal lamina, ensheathing the abluminal membranes of BVECs (FiguRe 2) [63] . These foot processes can also form direct connections to neurons. As such, astrocytes likely play a critical role in regulating brain iron absorption and metabolism at the junction of the BBB [78] . This unique arrangement allows astrocytes to act as gatekeepers in regulating the iron transport properties of the BBB. Astrocytes do not express TfR [78] , although this is somewhat controversial [79] . They may, however, take up significant amounts of NTBI as a primary ironuptake pathway. Interestingly, DMT1 has been shown to have polarized expression in astrocytes, being only expressed in the endfoot processes that associate with the BBB [80] . Therefore, iron released by BVECs may quickly be taken up by nearby astrocytes through DMT1 (nonvesicular iron import pathway IN3; FiguRe 1 and FiguRe 2) and redistributed to the extracellular space in the brain parenchyma. Astrocytes have also been implicated in metabolizing heme, releasing iron degraded by heme oxygenase-1 [81] .
Ferroportin (nonvesicular iron export pathway EX3; FiguRe 1) forms the major iron efflux pathway in astrocytes [73] . Fpn is coupled to a GPI-anchored form of Cp, the Cu-dependent ferroxidase that can rapidly oxidize released Fe 2+ to its less reactive Fe 3+ form [35] . Astrocytes cultured from Cp-deficient mice are unable to export iron, even though they have normal iron uptake [82] . Yet normal iron export is restored by simply supplying soluble Cp to the cell culture medium. Because astrocytes are closely associated to the brain's vasculature and have a high capacity for iron accumulation, yet store little iron, they may be involved in brain iron distribution after uptake. Consistent with this notion, patients with aceruloplasminemia (taBle 1) are observed to have primary iron accumulation in the astrocytic foot processes along the BBB, forming inclusions known as 'grumose foamy spheroid bodies' [83] .
Iron transport in neurons
Iron is required for many neuronal functions and is a cofactor required for the synthesis of dopaminergic neurotransmitters [5, 8] . A substantial portion of oxygen consumption in the body (~20%) relies on mitochondrial respiration in the brain, of which iron is an essential trophic factor, required for oxygen consumption and ATP generation [6] . As TfR is expressed in central neurons, the Tf-TfR system may be an important pathway for neurons to acquire iron. Furthermore, both DMT1 and TRPML1 are highly expressed in neurons [37, 55] . Since both proteins transport Fe 2+, but not Fe 3+ , a ferric reductase must exist in the endosomes and lysosomes of neurons. While Steap3 is shown to function in the endosomes of erythroid cells [48] , both Steap1 and -2 are expressed in the brain [52] . In addition, the stromal cell-derived receptor-2 [84] , a homologue of the duodenal ferrireductase DcytB [44] , is expressed in the brain. It is future science group unclear whether stromal cell-derived receptor-2 is localized to the endolysosomal membranes or the plasma membrane.
Neurons are also able to utilize NTBI as an iron source, where it forms significant stores of brain iron [64] . Although citrate and ascorbate bind Fe 3+ with affinities (K d ~10 -11 M) more than 10 10 -times lower than Tf (K d ~10 -23 M), they are much more abundant in the CSF/ISF than the plasma [37] . Hence citrate/ascorbatebound NTBI can reach sub-micromolar concentrations (<1 µM ) in the CSF [37, 38] . It has been demonstrated that NTBI may enter the neurons through several nonvesicular import mechanisms (IN3, IN4, IN5 and IN6; FiguRe 1) . DMT1, Zip14 (Slc39a14) [85] , voltage-gated Ca 2+ channels [86] and TRPC6 [87] [5, 7, 70] , suggesting that iron is taken up either for rapid utilization or secreted by the robustly detected iron exporter Fpn. Increased neuronal Ft expression, as seen in Irp2
-/-mice, may be toxic and has been reportedly associated with extrapyramidal neurodegeneration [27] .
Abnormal intracellular iron transport in neurons may cause neurodegeneration. Cytosolic iron overload causes oxidative stress by increasing ROS levels via the Fenton reaction. Since neuronal iron is transported along axons and dendrites, iron overload in neurons may cause both neuronal cell death and axonal degeneration. Impaired endolysosomal iron release may result in intralysosomal iron overload, which in turn increases free radical oxides and facilitates the formation of 'lipofuscin' (or 'aging pigment') [26, 88] . Lipofuscin accumulation may affect the normal function of lysosomes, such as autophagy, resulting in neuronal cell death and axonal degeneration. Impaired intracellular iron transport may also cause other neuronal dysfunctions. For example, hippocampus-specific inactivation of DMT1 in mice results in iron deficiency in the hippocampal neurons and impaired learning and memory [89] .
Iron transport of oligodendrocytes
Most of the histochemically detectable iron in the brain is found within oligodendrocytes, likely reflecting the high demand of iron required for myelination [6] . These cells are also the predominant producers of Tf in the brain [66] , suggesting an indirect role for oligodendrocytes in neuronal iron transport. Ferritin, traditionally considered to be an intracellular iron storage protein, is also present in the serum [13] and is known to bind the extracellular face of oligodendrocytes in vivo [90] . The recent identification of Ft receptors suggests that oligo dendrocytes primarily take up NTBI iron from the ISF by a Ft-dependent mechanism (vesicular import pathway IN1; FiguRe 1) [69, 90] . Consistent with the stringent iron requirements for axon myelination (FiguRe 2) , the Ft receptor Tim-2 is highly expressed in oligodendrocytes, but not astrocytes [90] .
CNS iron homeostasis, dyshomeostasis & novel therapies
Regulation of brain iron transport Iron uptake across the BBB is dependent on the brain's iron status. During development or inadequate iron supply conditions, the transport rate of iron into the brain is significantly increased [91] . However, this is not associated with increased TfR expression by BVECs, rather TfR expression is upregulated in neurons during periods of inadequate circulating iron [64] . Therefore, multiple regulatory mechanisms may exist to control iron levels in the brain, independent of peripheral iron status. Consistent with this notion, during peripheral iron overload, such as is seen in patients with hemochromatosis, brain iron levels are not elevated or disrupted [66] .
Key proteins involved in iron metabolism are regulated post-transcriptionally by the iron responsive element-iron regulatory proteins (IRE-IRP) system in mammalian cells [4, 28] . IRPs are cytosolic iron-sensing proteins that, when cells are iron-depleted, interact with RNA transcripts containing a stem-loop structure known as an IRE [4] . IREs are present in many key proteins involved in iron acquisition, transport and storage. Low cytosolic iron levels cause two homologous IRPs (IRP1 and IRP2) to inhibit Ft and Fpn translation and to stabilize mRNA transcripts of TfR1 and DMT1 [13] . In iron-replete cells, neither IRP1 nor -2 binds IREs and Ft/Fpn expression increases while TfR/DMT1 expression decreases. The role of the IRE-IRP network in regulating systemic iron homeostasis has been well reviewed elsewhere [28] .
Iron transport in the brain is also regulated by the IRE-IRP system. In brain tissues from Irp2 -/-mice, Ft/Fpn expression is significantly increased.
future science group Conversely, TfR levels were found to be decreased, consistent with the notion that IRP2 ablation may constitute an inability to stabilize TfR transcripts [4, 28] . Although IRP double knockout mice (Irp1 -/-/Irp2 -/-) do not survive, Irp2
-/-mice exhibit microcytic anemia and progressive neurodegeneration [27] . Interestingly, brain iron accumulation precedes degeneration by several months in these mice [27] . Moreover, regions of brain iron accumulation in young mice accurately predict sites of CNS neurodegeneration. This work represents another example of support for the idea that defects in iron metabolism can act in a causal manner in CNS disorders.
Iron dyshomeostasis in animal models of CNS disorders In Irp2
-/-mice, immunolabeling of Ft revealed subunits along the length of axons, suggesting that Ft is transported from the site of synthesis (soma) to the axons, prior to axonal degeneration. Lysosomal turnover of Ft-Fe complexes at the synaptic terminal may lead to increased reactive Fe 2+ levels and oxidative stress [84] .
Consistent with this notion, axonal iron staining of Irp2
-/-mice is significantly greater than the wild-type control [27] .
Increased DMT1 expression has also been shown to be associated with neurodegeneration. Salazar et al. report that the transporter contributes to neurodegeneration in animal models of PD [32] . Using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse intoxication model of PD, the authors demonstrate that DMT1 expression increases in the ventral mesencephalon, leading to iron accumulation, increased oxidative stress and dopaminergic cell death. A hypomorphic mutation that impairs iron transport (G185R) in DMT1 was sufficient to protect rodents against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduction of neuro degeneration, suggesting a critical role for DMT1-mediated neuronal iron uptake into regions of the brain commonly affected in animal models of PD. Consistent with a role for iron-mediated toxicity in the animal models of PD, Kaur et al. used transgenic expression of Ft (as a genetic iron chelator) to demonstrate its protective effect on dopaminergic neurons in the SN after injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [31] . Similar results were obtained using oral administration of the iron chelator Clioquinol [31] .
Mutations in TRPML1 cause the neurodegenerative disorder ML4. Dong et al. propose that the excessive accumulation of intralysosomal iron leads to the formation of iron-catalyzed ROS and, eventually, to formation and accumulation of lipofuscin in post-mitotic cells, such as neurons [26] . Progressive damage to cellular macromolecules eventually leads to psychomotor retardation and retinal degeneration. It is noteworthy that ML4 cells exhibit intralysosomal iron overload and concurrent cellular iron deficiency. Cellular iron deficiency observed in ML4 cells may lead to dysregulation of the IRE-IRP regulatory system, further enhancing iron mislocalization and neurodegeneration. Thus, it is the cellular iron mislocalization, but not the overall cellular iron content, that causes neuronal cell death and degeneration.
Therapeutic targets
Two principal iron-related therapies for neurodegenerative disorders are anti-oxidant or chelation therapies. While anti-oxidant therapy aims to attenuate oxidative stress by decreasing the amount of ROS, chelation therapy is geared toward suppressing radical formation by decreasing the level of the catalyst, (i.e., iron). Desferrioxamine (DFO), a wellknown iron chelator, has been shown to slow cognitive decline in Alzheimer's patients [29] and Clioquinol has demonstrated neuro protective success in animal models of PD [31] . Most therapeutic agents, however, are hampered by pitfalls. For example, Clioquinol has notably neurotoxic side effects [30] , and DFO crosses the BBB poorly [29] .
Several new technologies may provide novel targeting methods for iron chelators. For example, DFO can be incorporated into drug-delivery systems with nanoparticles [92] . Iron chelator-nanoparticle systems allow therapeutic agents to cross the BBB by using lowdensity lipoprotein transport machinery for uptake [93] . This approach minimizes toxicity by allowing the chelator-nanoparticle complex to be transported, together with iron, out of the brain. These carrier systems may be able to efficiently deliver any iron-related therapeutic compound or transgenic fusion protein to the CNS, equivalent to a 'genetic iron chelator'. As iron accumulation in neurodegenerative diseases is often 'regional', research may eventually lead to targeting strategies specifically to regions of interest in the brain that are particularly vulnerable to iron accumulation and iron-mediated toxicity, such as the SN. Iron overload can also be a 'subcellular' problem, as seen in the ML4 cells, which exhibit cytosolic iron deficiency and future science group concurrent intralysosomal iron overload [26] . Therefore, iron chelators that target the lysosome, such as a-lipoic acid plus (LAP) may specifically reduce intralysosomal iron overload and subsequent lipofuscin formation [94] . Although LAP has the potential to cross the BBB, its conjugation with nanoparticles may greatly facilitate transport into and out of the brain. The specificity and efficacy of iron chelators can be tested in the aforementioned animal models.
Finally, gene therapy may provide an alternative neuroprotection strategy. Using genetic engineering approaches to express chimeric Tf R fused to a peptidomimetic monoclonal antibody, Boado et al. demonstrate that TfR can serve as a viable drug-delivery mechanism to cross the BBB for therapeutic fusion proteins in mice [95] . Furthermore, Chang et al. have shown that Tf-bound nanoparticles interact with cells in a specific manner and enter cells via the caveolae pathway [92] . As the mechanisms of brain iron transport begin to emerge, new pharmacological targets and drug-carrier systems are likely to develop.
Future perspective
Several genetic disorders of iron metabolism clearly cause degenerative symptoms. These include inherited mutations in pantothenate kinase-2 leading to NBIA type I, mutations in FLT1 (encoding l-Ft) leading to neuroferritinopathy, mutations in PLA2G6 leading to INAD1, and mutations in Cp leading to aceruloplasminemia. Numerous neurodegenerative diseases have also been proposed as being related to changes in iron homeostasis, including PD, AD, Huntington's, Friedreich's ataxia, restless leg syndrome, ischemic/hemorrhagic stroke and multiple sclerosis. As a clearer picture of brain iron metabolism begins to come into focus, future research will be able to help develop iron-centric therapies for these CNS disorders. Continuing efforts should be made to gain a mechanistic understanding of iron transport across the abluminal membrane of BVECs, the roles of glia cells in regulating brain iron uptake and, finally, how neuronal iron accumulation may lead to neuro degeneration and CNS disease progression. Brain iron accumulation
Executive summary
Excessive iron levels lead to oxidative stress and, in the brain, cause neurodegeneration.
Nonheme iron can enter and exit mammalian cells by two distinct mechanisms: vesicular and nonvesicular.
Dietary ferric iron is transported across intestinal enterocytes in a coordinated effort between the apical ferrireductase DcytB and the iron importer DMT1, followed by its export via ferroportin (Fpn) and a basolateral ferrioxidase, binding to transferrin (Tf) and entry into plasma.
Tf-bound iron is taken into erythroid precursor cells by the membrane-bound transferrin receptor (TfR) via endocytosis, released in the early endosome, reduced by Steap3, and transported into the cytosol by DMT1, where it contributes to the labile iron pool, is transported to mitochondria, stored in ferritin or transported out of the cell via Fpn.
Mutations in TRPML1, a protein involved in iron release from the late endosome and lysosomes, cause the neurodegenerative disease mucolipidosis type IV, which causes some patients to exhibit iron-deficiency anemia. The brain cannot directly take up iron from the circulatory system; rather, iron crosses brain vascular endothelia cells (BVECs) in a multistep transcellular process similar to that of enterocytes in the duodenum.
The Tf-TfR system plays a primary role in iron uptake across the blood-brain barrier (BBB), while the extent to which iron is taken up by Tf homologues, such as lactoferrin or melanotransferrin, is still unclear.
While there is controversy as to whether DMT1 is expressed in BVECs, TRPML1 has a ubiquitous expression pattern and is likely to play an important role in endolysosomal iron release. The role of other iron release proteins, such as ZIP8 and TRPML2, is not yet known.
The iron-export mechanism across the abluminal membrane is undefined; however, both vesicular and nonvesicular exocytotic mechanisms may coexist in BVECs.
As astrocytes are closely associated to the brain's vasculature and have a high capacity for iron accumulation, yet store little iron, they may be involved in brain iron distribution after uptake, acting as gatekeepers in regulating the iron transport properties of the BBB.
Little iron is typically stored in neurons and, since neuronal iron is transported along axons and dendrites, iron overload may cause both neuronal cell death and axonal degeneration.
Most detectable iron in the brain is found within oligodendrocytes, as is the high expression of the recently identified ferritin receptor (Tim-2), likely reflecting the high demand of iron required for axon myelination.
Iron transport in the brain is governed by key proteins regulated post-transcriptionally by the iron-responsive element-iron regulatory proteins system. Cellular iron mislocalization, but not the overall cellular iron content, causes neuronal cell death and degeneration.
New technologies for neuroprotection may provide novel targeting methods, including nanoparticle drug-delivery systems in conjunction with iron chelators as well as gene therapy strategies.
future science group manifests at regional, cellular and subcellular levels. Understanding the cellular and intercellular transport mechanisms may not only reveal the pathogenic cause of neurodegenerative diseases, will also be necessary for designing effective therapeutic approaches to take advantage of newly developed drug-targeting methods. 
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